JP Morgan Chase
KYMR icon

JP Morgan Chase’s Kymera Therapeutics KYMR Stock Holding History

JP Morgan Chase’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.97M Sell
125,419
-5,934
-5% -$470K ﹤0.01% 2675
2025
Q4 		$10.2M Sell
131,353
-61,346
-32% -$4.14M ﹤0.01% 2669
2025
Q3 		$10.9M Sell
192,699
-15,023
-7% -$678K ﹤0.01% 2635
2025
Q2 		$9.06M Buy
207,722
+160,848
+343% +$5.54M ﹤0.01% 2646
2025
Q1 		$1.28M Buy
46,874
+9,809
+26% +$358K ﹤0.01% 4177
2024
Q4 		$1.49M Sell
37,065
-103,426
-74% -$4.67M ﹤0.01% 4355
2024
Q3 		$6.65M Buy
140,491
+95,547
+213% +$4.22M ﹤0.01% 2989
2024
Q2 		$1.34M Sell
44,944
-410,992
-90% -$14.2M ﹤0.01% 4072
2024
Q1 		$18.3M Sell
455,936
-56,310
-11% -$2.01M ﹤0.01% 1959
2023
Q4 		$13M Sell
512,246
-109,746
-18% -$1.96M ﹤0.01% 2206
2023
Q3 		$8.65M Sell
621,992
-33,979
-5% -$683K ﹤0.01% 2376
2023
Q2 		$15.1M Buy
655,971
+89,005
+16% +$2.55M ﹤0.01% 1927
2023
Q1 		$16.8M Buy
566,966
+15,443
+3% +$498K ﹤0.01% 1816
2022
Q4 		$13.8M Sell
551,523
-10,349
-2% -$276K ﹤0.01% 1977
2022
Q3 		$12.2M Sell
561,872
-41,506
-7% -$1.09M ﹤0.01% 1998
2022
Q2 		$11.9M Buy
603,378
+439,903
+269% +$10.3M ﹤0.01% 2005
2022
Q1 		$6.92M Sell
163,475
-17,158
-9% -$725K ﹤0.01% 2721
2021
Q4 		$11.5M Buy
180,633
+14,698
+9% +$856K ﹤0.01% 2327
2021
Q3 		$9.75M Buy
165,935
+1,500
+0.9% +$87K ﹤0.01% 2411
2021
Q2 		$7.97M Buy
164,435
+105,578
+179% +$4.58M ﹤0.01% 2629
2021
Q1 		$2.29M Buy
58,857
+36,771
+166% +$2.21M ﹤0.01% 3619
2020
Q4 		$1.37M Buy
+22,086
New +$1.08M ﹤0.01% 3746

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

JP Morgan Chase's KYMR Position: Q1 2026 in Review

JP Morgan Chase reduced its Kymera Therapeutics (KYMR) stake by 4.5% in Q1 2026, selling an estimated $470K and leaving 125,419 shares worth $9.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.

JP Morgan Chase first reported a position in KYMR in Q4 2020 and has held it in 22 quarters since. The position peaked at $18.3M in Q1 2024. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • JP Morgan Chase held 125,419 shares of Kymera Therapeutics worth $9.97M as of Q1 2026.
  • JP Morgan Chase sold 5,934 Kymera Therapeutics shares in Q1 2026, an estimated $470K.
  • Kymera Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2675 holding.
  • JP Morgan Chase first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Kymera Therapeutics position peaked at $18.3M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.